Lenacapavir Tablet: Clinical Trials

10 trials of Lenacapavir Tablet, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 active not recruiting, 5 recruiting. 6 Phase 2, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Active not recruiting 4, Recruiting 2
Phase 34Recruiting 3, Active not recruiting 1

Follow Lenacapavir Tablet: new trials by email Literature Review of Lenacapavir Tablet trials Research Report on Lenacapavir Tablet

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet - HIV-1-infection
Phase 2 / Phase 3RecruitingGilead Sciences7002026-07-292026-11-10
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV Infections
Phase 3RecruitingGilead Sciences5902026-07-142026-08-14
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV-1-infection
Phase 3RecruitingGilead Sciences5902026-07-142026-07-30
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet - HIV-1-infection
Phase 2RecruitingGilead Sciences1752026-06-152026-11-10
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF) - HIV Infections
RecruitingGilead Sciences30002026-03-172026-10-21
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
Lenacapavir Injection, Lenacapavir Tablet - HIV Pre-exposure Prophylaxis
Phase 3Active not recruitingGilead Sciences3392025-07-222026-08-28
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection
Phase 2Active not recruitingGilead Sciences2682024-10-072026-06-15
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection
Phase 2Active not recruitingGilead Sciences1812023-12-132026-08-13
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection
Phase 2Active not recruitingGilead Sciences2532023-11-172026-08-17
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Teropavimab, Zinlirvimab, Lenacapavir Tablet - HIV-1 Infection
Phase 2Active not recruitingGilead Sciences832023-05-152026-04-27

Conditions studied

HIV Infections (2)

Sponsors

Gilead Sciences (10)

Countries

United States (9)  ·  Australia (3)  ·  Canada (3)  ·  Puerto Rico (3)  ·  France (1)  ·  Germany (1)  ·  Japan (1)  ·  Spain (1)  ·  United Kingdom (1)

Results publications

PMID 41498432, PMID 41720146

NIH funding

2025 (2), 2023 (1)